Skip to main content

Table 2 Estimated characteristics of the sites

From: The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease

Site Country Median EIR derived from MAP PfPR2–10 Median EIR adjusted for trial prevalence and incidence in the control DHS estimate of access to effective treatment Estimated access to effective treatment in trial
Kilifi Kenya 1.1 0.15 45.0 53.9
Korogwe Tanzania 2.0 0.12 49.2 35.3
Manhica Mozambique 2.4 0.15 35.8 46.7
Lambarene Gabon 4.3 0.18 16.1 60.8
Bagamoyo Tanzania 2.9 0.23 55.4 54.1
Lilongwe Malawi 6.3 0.44 43.3 52.6
Agogo Ghana 6.3 2.1 42.5 63.5
Kombewa Kenya 5.2 8.7 48.8 59.3
Kintampo Ghana 19.5 13.5 40.5 53.9
Nanoro Burkina Faso 89.2 75.6 37.4 39.4
Siaya Kenya 34.5 86.6 48.8 50.9